The nature and significance of the distribution of mutations by base pair in the p53 gene have been the subject of investigation in recent years because of the importance of this gene in control of the cell cycle, DNA repair and synthesis, cell differentiation, and cell death (1) (2) (3) (4) (5) (6) (7) (8) (9) . Mutations in the p53 gene have been found in many types of cancer and may be the most common mutation observed in human cancers. In lung cancer, p53 mutations have been found in 56% of tissue samples, and in colorectal, esophageal, ovarian, pancreatic, and skin cancers, prevalences of 44-50% have been reported (4) . Mutations occur at many base pairs throughout the gene, with higher frequencies reported in exons 5-8 than at other exons and high frequencies occurring at specific codons (4, (10) (11) (12) . The diversity in p53 mutations has suggested the possibility of correlating exposures with specific p53 mutations, for example, vinyl chloride and mutations at A:T base pairs in angiosarcomas, ultraviolet radiation and CC->TT changes in skin cancer, aflatoxins and G-+T mutations in liver cancer, or G:C to A:T transitions associated with mustard gas exposure in lung cancer patients (13) (14) (15) (16) (17) (18) (19) . Such epidemiologic correlations may be supported by laboratory studies showing specific mutations associated with specific mutagens. For example, n-ethyl-nnitrosourea, an alkylating agent associated with carcinogenesis in the gut and other tissues, induces G-÷A transitions at codon 248 in human fibroblasts (20) .
These observations suggest that in cancer cells derived from tumors in different organs, p53 mutational spectra can be seen as the fingerprints of the carcinogens that caused the cancer (10, 11, 19, (21) (22) (23) . The hypothesis that environmental carcinogens correlate strongly with p53 mutational spectra is the basis for suggestions that certain p53 mutations can be interpreted as markers of exposure. Some examples of these suggestions are 1) that the presence of p53 mutations in esophageal carcinoma patients with and without human papilloma virus involvement is evidence of the role of environmental carcinogens in esophageal carcinogenesis (24) ; 2) that varying frequencies of microdeletions, transitions, and transversions in different breast cancer populations are compatible with the role of different environmental carcinogens contributing to breast cancer carcinogenesis in different populations (25) ; 3) that differences in proportions of transversions in Japanese and American prostate cancer patients suggests variation in etiologic factors between the two populations (26) ; and 4) that observations of the presence of G-+T changes in breast cancer and those observed in lung cancer (which the authors maintain are probably caused by exogenous mutagenic chemicals) suggest that these breast cancers were similarly caused by exogenous chemicals (23) .
Researchers have characterized mutational variation primarily by summarizing aggregate base pair changes throughout the gene and presenting the data in pie charts, histograms, or tables. These analyses indicate variation in base pair changes by cancer: for example, differences in the proportions of A:T to C:G changes in cancers of the skin, nasopharynx, oral cavity, and pharynx/larynx, or differences in mutation type (deletion, base pair substitution, splice site, etc.) (4, 21, 2 (4, 31, 32) .
To fully evaluate the assumption that p53 mutational spectra reflect specific environmental carcinogens, it is necessary to fully describe and characterize variation in p53 mutational spectra; the second step is to correlate variation in p53 mutational spectra with specific exposures. In this paper, we extend the evaluation of p53 mutational variation by analyzing an internationally available database of p53 mutations. We expand on previous analyses by characterizing differences in frequent codon sites in five cancers-breast, colorectal, liver, lung, and ovarian-and by examining differences by cancer in base pair changes at six codon sites that have been identified in the literature as p53 mutation hot spots.
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We also analyzed the predicted amino acid change at codon sites by cancer and tested for statistical significance by comparing relative frequencies. Because the database did not contain information on exposures, we were not able to correlate mutational variation with exposures.
Methods
The European Molecular Biology Library has compiled reports from individual studies to produce an aggregated database of p53 mutations (31) (32) (33) G-iT Three-dimensional histograms of mutation frequency by base pair change and cancer or amino acid change and cancer were useful in visualizing the distinct patterns at each of the codons analyzed (Figs. 1-6 ). Figure 4A and Figure 5A and B show the more complex pattern of mutations occurring at codon 273. Six different base pair changes occurred, resulting in six different amino acid changes; however, most of the amino acid changes are to His or Cys except for lung cancer, where Arg tO Leu (G->T) changes appeared more frequently. In colorectal cancer, Arg to His and Arg to Cys (G-4A and C-*T) were the only changes reported at this codon.
The three-dimensional histograms were used to suggest comparisons for statistical analysis, and Table 5 changes in breast cancer was compared to its prevalence in liver, lung, and ovarian cancers; the prevalence of the same changes in colorectal cancer was also compared to the prevalence in liver, lung, and ovarian cancers. At codon 248, Arg to Trp (C-iT) changes were associated with colorectal cancer only (compared to the other four cancers), but Arg to Gln (G-A) changes were associated with both breast and colorectal cancers compared to the other three cancers. Arg to Leu (G-*T) changes were associated with lung cancer only. At codon 245, glycine (Gly) to serine (Ser) (G-A) changes were associated with colorectal and ovarian cancers, Gly to aspartic acid (Asp) (G-*A) was associated with colorectal cancer only, and Gly to Cys (G--T) was associated with lung cancer only. At codon 249, Arg to Ser (G->T and G-*C) changes were strongly associated with liver cancer only. At codon 175, Arg to His (G-A) changes were associated with breast and liver cancers, but not with colorectal, lung, or ovarian cancers. At codon 273, Arg to His (G-A) changes were associated with breast, colorectal, and ovarian cancers, Arg to Cys (C-*T) changes were associated with colorectal and ovarian cancers, and Arg to Leu (G-4T) changes were associated with lung cancer only. At codon 282, Arg to Trp (C-*T) changes were associated with colorectal, lung, and ovarian cancers, but not with breast or liver cancers. All of the above associations were statisticaly significant.
Discussion
The five most frequent sites of p53 mutations were different in breast, colorectal, lung, liver, and ovarian cancers. This is consistent with previous reports in the literature that hot spots and mutational spectra vary by cancer (1, 4, 12, 29, 32) . The variation in hot spots is not explained by the predominance of specific base pair changes in each cancer. Thus, while G->T base pair changes were the most frequent changes in both liver and lung cancers, the two cancers shared only two hot spots. The great majority (1 18/145) of G-iT changes in liver cancer occurred at codon 249, its number one hot spot, but codon 249 was not a hot spot in lung cancer. Even at a shared hot spot, codon 273, different patterns of base pair changes were observed, with C-*T more frequent in liver cancer and G-*T more frequent in lung cancer. In some of the cancers, the percentages of mutations were low even at the most frequent sites, suggesting the need to further define the term hot spot and also suggesting that some cancers may not have true hot spots for p53 mutations.
In (4, 35) .
Inferences drawn from these data are limited by the data quality and by the lack of crucial information, particularly complete sequencing of the p53 gene and ascertainment of exposure histories. In breast cancer, 22% of p53 mutations have been reported to lie outside exons 5-8, although all missense mutations were reported within exons 5-8; thus, analyses relying on studies with differences in the exons sequenced may report different results (36) .
Inferences are also limited by the sample, a nonrandom, nonrepresentative selection of patients that may not truly reflect the distribution of p53 mutations in these cancers. The database is also limited by the absence of data describing age, gender, ethnicity, exposure history, severity of illness, co-morbidity, medications, and other characteristics of the patients. It was not possible to assess whether this was a representative sample of patients or which of these patient characteristics could have affected the overall distribution of mutations observed in the database.
The variation in p53 mutation distributions is more complex than has been previously described. The distributions vary by cancer in the sites (hot spots) of frequent mutations, the relative frequencies of mutations at hot spots, and specific base pair and amino acid changes at individual codons. Specific amino acid changes are associated with different cancers, and these patterns were statistically significant. Variations in organ-specific exposures and variations in organ-specific clonal selection factors may explain these associations, but a definitive assessment of the contribution of these forces to variation, as well as description of other correlates of p53 mutation distributions, awaits further epidemiologic and laboratory research.
A great deal of attention has been focused on the relationship between mutagens and observed p53 mutations without adequately considering the effects of clonal selection and without adequately considering the combined effects of different mutagens on p53 mutational distributions. Thus, while mutagens may cause distinct p53 mutations, it is not clear how such patterns might be shaped by exposure to multiple mutagens or by clonal selection forces. It is also not clear whether the correlation between mutagen and p53 mutational distributions will be consistently observed in molecular epidemiologic studies after modification by clonal selection. There is much work to be done in characterizing the extent and nature of variation in p53 mutation distributions by cancer. Before describing the extent of such variation, it seems premature to conclude that the vari-ation is a marker for or evidence of the exposure that caused the cancer and that no other factors influence the distribution ofp53 mutations.
